LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 33 of 497
Next
>>
>
801 to 825 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CP466722	0.37	uM	LJP5	3	I10	72	hr	1097	3838	3769	1.0182	1.0256
BT-20	Crizotinib	0.37	uM	LJP5	1	A22	72	hr	1097	3110	3769	0.8250	0.7532
BT-20	Crizotinib	0.37	uM	LJP5	2	A22	72	hr	1097	3363	3769	0.8922	0.8479
BT-20	Crizotinib	0.37	uM	LJP5	3	A22	72	hr	1097	3329	3769	0.8831	0.8352
BT-20	Momelotinib	0.37	uM	LJP5	1	P10	72	hr	1097	3181	3769	0.8439	0.7798
BT-20	Momelotinib	0.37	uM	LJP5	2	P10	72	hr	1097	3730	3769	0.9895	0.9852
BT-20	Momelotinib	0.37	uM	LJP5	3	P10	72	hr	1097	3511	3769	0.9314	0.9033
BT-20	Dasatinib	0.37	uM	LJP5	1	D04	72	hr	1097	1401	3769	0.3717	0.1137
BT-20	Dasatinib	0.37	uM	LJP5	2	D04	72	hr	1097	1623	3769	0.4306	0.1967
BT-20	Dasatinib	0.37	uM	LJP5	3	D04	72	hr	1097	1365	3769	0.3621	0.1002
BT-20	Dasatinib	0.37	uM	LJP6	1	I04	72	hr	1097	1177	3769	0.3122	0.0298
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1097	1009	3769	0.2677	-0.0330
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1097	1142	3769	0.3030	0.0167
BT-20	Dovitinib	0.37	uM	LJP5	1	E22	72	hr	1097	1664	3769	0.4414	0.2121
BT-20	Dovitinib	0.37	uM	LJP5	2	E22	72	hr	1097	1640	3769	0.4351	0.2031
BT-20	Dovitinib	0.37	uM	LJP5	3	E22	72	hr	1097	1570	3769	0.4165	0.1769
BT-20	Enzastaurin	0.37	uM	LJP5	1	D16	72	hr	1097	3909	3769	1.0370	1.0522
BT-20	Enzastaurin	0.37	uM	LJP5	2	D16	72	hr	1097	4043	3769	1.0725	1.1023
BT-20	Enzastaurin	0.37	uM	LJP5	3	D16	72	hr	1097	4358	3769	1.1561	1.2202
BT-20	Erlotinib	0.37	uM	LJP5	1	M22	72	hr	1097	3178	3769	0.8431	0.7786
BT-20	Erlotinib	0.37	uM	LJP5	2	M22	72	hr	1097	3320	3769	0.8807	0.8318
BT-20	Erlotinib	0.37	uM	LJP5	3	M22	72	hr	1097	3490	3769	0.9258	0.8954
BT-20	Foretinib	0.37	uM	LJP5	1	H10	72	hr	1097	1587	3769	0.4210	0.1833
BT-20	Foretinib	0.37	uM	LJP5	2	H10	72	hr	1097	1753	3769	0.4650	0.2454
BT-20	Foretinib	0.37	uM	LJP5	3	H10	72	hr	1097	1562	3769	0.4144	0.1739

|<
<<
Previous
Page 33 of 497
Next
>>
>
801 to 825 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)